FDAnews
www.fdanews.com/articles/97931-accera-announces-results-from-ketasyn-study

Accera Announces Results From Ketasyn Study

August 31, 2007

Accera announced that recent data from a Phase II study of its lead compound Ketasyn in age-associated memory impairment (AAMI) showed that the candidate has a positive effect on memory in older adults. 

According to Accera, the randomized, double-blind, placebo-controlled, parallel, multicenter trial was conducted at six centers in the U.S. One hundred fifty-nine subjects diagnosed with AAMI received either Ketasyn or placebo for 90 days followed by a two-week washout period. 

On days 0, 30, 60, 90 and 104, subjects were evaluated through a battery of neuropsychometric tests that measure various aspects of memory and cognition.

Ketasyn showed significant efficacy in tests of memory. On average, subjects taking Ketasyn performed significantly better on the First-Last Name Association test than subjects taking placebo, the company said. 

In the Name-Face Recognition test, Ketasyn subjects under 59 improved more than placebo subjects at day 90, the company added.